Page 7 - Eric Soyer News Today

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of ... Erytech Pharma S.A.April 19, 2021 GMT ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer No dose-limiting toxicity reported in the first dose cohort Encouraging clinical activity observed in first patients Trial will be escalat...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business Update Erytech Pharma S.A.March 4, 2021 GMT ERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business Update Lyon (France) and Cambridge, MA (U.S.), March 4, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis Erytech Pharma S.A.February 8, 2021 GMT ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis                                                         The Independent Data Monitoring Committee (IDMC) recomme...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Erytech Pharma S.A.January 6, 2021 GMT ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic dru...

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer A total of 510 patients enrolled Events required to trigger interim superiority analysis accrued Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021 LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances ins...

Erytech Pharma S.A.: ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer Events required to trigger interim superiority analysis accrued Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021 LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood...

The event will be held virtually, with all corporate and institutional participants joining remotely. A webcast of the event will be available by clicking here and will be accessible via ERYTECHs website at http://www.erytech.com/investors/webcast/ About ERYTECH and eryaspase ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a nove...

Erytech Pharma S.A.: ERYTECH to Present at the JMP Securities Hematology Summit ERYTECH Pharma cells, t Tuesday December 15 by The event will be held virtually, with all corporate and institutional participants joining remotely. A webcast of the event will be available by clicking hereand will be accessible via ERYTECHs website at http://www.erytech.com/investors/webcast/ About ERYTECH and eryaspase ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-b...